Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine : a phase 3 randomized clinical trial

Autor: Johanna Spaans, Bebi Yassin-Rajkumar, Peter Ruane, Timo Vesikari, Saul N. Faust, Amina Z Haggag, Bruce Rankin, Benita Ukkonen, Michael Levin, Michael Manns, Satu Kokko, Gerald Vallieres, Carl Griffin, David E. Anderson, Vlad Popovic, Francisco Diaz-Mitoma, Mary B Manning, Azhar Toma, Hamilton Sah, Clancy L. Cone, Nathalie Machluf, Nathan Segall, Williams Hayes, Mark A. Turner, Aino Forsten, Outi Laajalahti, Maija Rössi, Anitta Ahonen, Mark E Kutner, Naveen Garg, M N Ramasamy, Adam Finn, Isabel Leroux-Roels, Olli Henriksson, Dennis Reich, Geert Leroux-Roels, Pierre Van Damme, Pauliina Paavola, Catherine Cosgrove, Barbara E. Rizzardi, Ilkka Seppä, Ronnie Aronson, Samir Arora

Publikováno v: JAMA NETWORK OPEN
JAMA Network Open
Vesikari, T, Finn, A, van Damme, P, Leroux-Roels, I, Leroux-Roels, G, Segall, N, Toma, A, Vallieres, G, Aronson, R, Reich, D, Arora, S, Ruane, P J, Cone, C L, Manns, M, Cosgrove, C, Faust, S N, Ramasamy, M N, Machluf, N, Spaans, J N, Yassin-Rajkumar, B, Anderson, D, Popovic, V, Diaz-Mitoma, F 2021, ' Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine : A Phase 3 Randomized Clinical Trial ', JAMA Network Open, vol. 4, no. 10, e2128652, pp. e2128652 . https://doi.org/10.1001/jamanetworkopen.2021.28652
JAMA Netw Open

Importance There is a need for improved immunogenicity of hepatitis B virus (HBV) vaccines among young adults with risk of infection. Objectives To demonstrate manufacturing equivalence of a 3-antigen (3A) HBV vaccine, evaluate noninferiority of sero

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fb4f067c6f9010c585085536e06f1af
https://hdl.handle.net/1854/LU-8759301

Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials

Autor: Charles P. Andrews, Myron J. Levin, Tino F. Schwarz, Lily Yin Weckx, Lidia Oostvogels, Covadonga Caso, Anthony L. Cunningham, Won Suk Choi, Angelo Pellegrino, Maria Luisa Rodriguez de la Pinta, Joon Hyung Kim, Tiina Korhonen, Edward M. F. Leung, Peter Eizenberg, Jackson H. Downey, David S.C. Hui, Janet E. McElhaney, Azhar Toma, Lars Rombo, Shelly A. McNeil, Wayne Ghesquiere, Roman Chlibek, Ilkka Seppa, Juan Carlos Tinoco, Silvia Narejos Perez, Daisuke Watanabe, Abiel Mascarenas de Los Santos, David O. Willer, Romulo E Colindres, Jose-Fernando Barba-Gomez, Anitta Ahonen, Anne Schuind, Carles Brotons Cuixart, Ferdinandus de Looze, Tommaso Staniscia, Alexander L. Thompson, Yeo Wilfred, Shinn-Jang Hwang, Iris Gorfinkel, Javier Díez Domingo, Meral Esen, Carla A. Talarico, Eugene Athan, Airi Poder, Johan Berglund, Jan Smetana, Pierre Gervais, Valentine Wascotte, Robert W. Johnson, Thiago Junqueira Avelino-Silva, Hideyuki Ikematsu, Karlis Pauksens, Maria Giuseppina Desole, Toufik Zahaf, Rodrigo Ribeiro dos Santos, Joan Puig Barbera

Publikováno v: Vaccine. 37(43)

Background Herpes zoster (HZ) risk appears to vary by sex and geographic ancestry/ethnicity. Methods In 2 randomized clinical trials, participants received 2 doses of adjuvanted recombinant zoster vaccine (RZV) or placebo intramuscularly, 2 months ap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c5902400bff974cc20b7af1945a024
https://pubmed.ncbi.nlm.nih.gov/31537443

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

Autor: Maarten Leyssen, Ilse Dieussaert, Laurence Fissette, Naresh Aggarwal, Shelly A. McNeil, Azhar Toma, Walthère Dewé, Scott A. Halperin, Joanne M. Langley, Jean-François Toussaint

Publikováno v: The Journal of Infectious Diseases

Background. Respiratory syncytial virus (RSV) is a leading cause of childhood bronchiolitis and pneumonia, particularly in early infancy. Immunization of pregnant women could boost preexisting immune responses, providing passive protection to newborn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb5dc52c1d253d4d4f6773a879160805
http://europepmc.org/articles/PMC5225248

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial

Autor: Jyoti Soni, Anne Schuind, Damien Friel, Paul Rheault, Bruce L. Innis, Ping Li, Murdo Ferguson, David J. Seiden, Anuradha Madan, Azhar Toma

Publikováno v: Vaccine. 35(15)

Background H7 influenza strains can cause severe and often fatal human infections, especially in the elderly. This phase II, observer-blind, randomized trial ( www.ClinicalTrials.gov : NCT01949090 ) assessed the immunogenicity and safety of a novel A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bb78b0e683d5bb02d493df3d682316e
https://pubmed.ncbi.nlm.nih.gov/28302407